Shenqi Fuzheng Injection Combined With Milrinone In Treatment Of Severe Heart Failure Research

Objective :Study prospectively the data which Shenqifuzheng Injection and Milrinonein treated the patients with severe heart failure.Analysis the clinical effect which Shenqifuzheng Injection and Milrinonein treated the patients with severe heart failure.Objects and Methods :90 patients with heart failure of Department of Cardiology in Jinan Third People’s Hospital from 2013 February to 2014 February. 46 men and 44 women, aged between 52~90 years old, average age is 75.10 ± 9.09 years old. All patients with cardiac function grade IV accorded with America New York Heart Association(NYHA) grading standard.90 patients were randomly divided into the dobutamine group, milrinone group,milrinone and Shenqi fuzheng Injection group.All groups were given Oxygen Inhalation, digitalis, diuretics, ACEI,small dose of beta receptor routine treatment. Dobutamine group was given dobutamine 2~3 μ g/(kg ? min)begining, the maximum capacity of 20 μ g/(kg ? min) continuous infusion, course of the disease is 10 days. Milrinone group,were given 50 μ g/Kg milrinone infusion first, and then 0.5μ g/Kg/min intravenous drip, course of the disease is 10 days. Milrinone and Shenqi fuzheng Injection group: On the basis of milrinone group, given Shenqifuzheng Injection 250 ml, once a day, course of the disease is 10 days.All the patients were phlebotomized NT-pro BNP before treatment and after 10- days after treatment. At the same time echocardiography, calculated LVEF. Statistics days of hospitalization, arrhythmia and1 years rehospitalization rate, mortality rate in each group. Statistical analysis was performed using SPSS 19 statistical software. All data measurement data shoeed with the mean±standard deviation, test of normality and homogeneity of variance before analysis, sample mean test between groups using t test, multiple sample mean test using analysis of variance, P<0.05 had significant difference.Results:1. Comparison of plasma NT-proBNP level with three groups after treatment, account for differences between plasma NT-pro BNP levels after treatment in the three groups had statistically significant.Between the three groups in the lower plasma NT-pro BNP level of SCM group >MLN group >DB group. 2. Comparison of cardiac LVEF levels with three groups after treatment, account for differences between cardiac LVEF levels after treatment in the three groups had statistically significant. Between the three groups in cardiac ultrasound LVEF level SCM group >MLN group >DB group. 3. Compared days of hospitalization in three groups, SCM group was lower than that in MLN group and DB group, MLN group and DB group were no difference. 4. Days of hospitalization and NT-pro BNP after treatment, P < 0.01, low correlation. 5. Days of hospitalization and LVEF after treatment, P < 0.01,correlation coefficient(R) of-0.334, is a low negative correlation. 6.LVEF and NT-pro BNP level correlation coefficient r=-0.205, P =0.048, P<0.0 5, negative weak relationship between both. 7. After treatment, NT-pro BNP, LVEF levels in group MLN,group SCM factorial analysis of variance,P < 0.01, the two drugs had statistical significance. 8.1years survival analysis of three groups, P>0.05, three groups of 1 years surviv al time. were no statistically significant differences. 9. Incidence of arrhythmia of the three groups, SCM group is more effective than MLN group, DB group to reduce the incidence of arrhythmia in patients with congestive heart failure. 10. 1 year rehospitalization rate of three groups, SCM group was significantly lower than MLN group, DB group. 11. Mortality of three groups, P>0.05, no statistical significance.Conclusion:1. Shenqifuzheng Injection combined with milrinone can obviously reduce plasma NT-pro BNP level of the severe congestive heart failure patients. 2. Shenqifuzheng Injection combined with milrinone can obviously improve the LVEF of severe congestive heart failure in patients. 3.Shenqifuzheng Injection combined with milrinone can obviously reduce the arrhythmias of severe congestive heart failure patients with.4. Shenqifuzheng Injection combined with milrinone can reduce readmission rate of severe congestive heart failure obviously. 5. Cardiac ultrasound LVEF and NT-pro BNP level of the heart failure patients has a weak negative relationship, days of hospitalization and NT-pro BNP levels after treatment had low positive correlation. 6. Shenqifuzheng Injection combined with milrinone can’t obviously prolong 1 years survival time and can’t reduce mortality of the patients with severe congestive heart failure.